American Association for Cancer Research Annual Meeting 2017

Patients with HER2-mutant lung cancer (n=26), breast cancer (n=25), bladder or urinary tract cancer (n=16), colorectal cancer (n=12), biliary tract cancer (n=9), endometrial cancer (n=7), cervical cancer (n=5), gastro-oesophageal cancer (n=5), and ovarian cancer (n=4), as well as patients with solid tumours not otherwise specified (n=32; of which 15 were HER2-mutant-postive and 17 were HER3-mutant-postive), were enrolled in this study. The proportion of patients who achieved an objective response defined by RECIST criteria at week 8 (the primary objective) was 32% (n=8) of patients with breast cancer, 22% (n=2) of patients with biliary tract cancer, 20% (n=1) of patients with cervical cancer, and 4% (n=1) of patients with lung cancer. CAR T-cell therapy for refractory NHL Frederick Locke (Moffitt Cancer Center, Tampa, FL, USA) presented the primary results from ZUMA-1, the first multicentre trial to investigate the use of an anti-CD19 chimeric antigen receptor T cell, axicabtagene ciloleucel, in patients with refractory aggressive non-Hodgkin lymphoma. Olaparib and temozolomide for small-cell lung cancer Anna Farago (Massachusetts General Hospital Cancer Center, Boston, MA, USA) presented results of an ongoing phase 1/2 trial of the use of olaparib tablets with temozolomide as second-line therapy for patients with small-cell lung cancer. PI3K and PARP inhibitor combination Panagiotis Konstantinopoulos (Dana-Farber Cancer Institute, Boston, MA, USA) presented results of an ongoing phase 1, 3+3 dose-escalation study assessing a combination of the PI3-kinase inhibitor BYL719 and the PARP inhibitor olaparib in patients with either recurrent ovarian cancer or breast cancer. Trop-2/SN-38 antibody-drug conjugate for metastatic SCLC In...